Translational Toxicology, Softcover reprint of the original 1st ed. 2016
Defining a New Therapeutic Discipline
Molecular and Integrative Toxicology Series

Coordinators: Hughes Claude L., Waters Michael D.

Language: English

158.24 €

In Print (Delivery period: 15 days).

Add to cartAdd to cart
Translational Toxicology
Publication date:
Support: Print on demand

158.24 €

In Print (Delivery period: 15 days).

Add to cartAdd to cart
Translational Toxicology
Publication date:
Support: Print on demand

Bringing together a distinguished interdisciplinary team of contributors,this volume provides a comprehensive exploration of translational toxicology?a systematic approach to developing therapeutic interventions that can protect against, mitigate, or reverse the effects of exposures.In particular, the book addresses modes of action and biomarkers, developmental risks of exposures, and potential translational toxicology therapeutics. The result is a compelling application of developmental toxicology in a new therapeutic discipline that is destined to become part of standard medical practice.

Translational Toxicology: Defining a New Therapeutic Discipline is an essential text for regulatory authorities, scientists, and physicians who are concerned with environmental exposures, public health, nutrition, and pharmaceutical research and development. Basic science, epidemiological, and clinical investigators will also find this book a significant resource.

I.Introduction.- The Opportunity to Translate Developmental Toxicology into a Therapeutic Discipline.- The Role of Toxicokinetics and Toxicodynamics in Developmental and Translational Toxicology.- II.Toxicant Modes of Action and Biomarkers.- Mutational Effects.- Ligand-Mediated Toxicology: Characterization and Translational Prospects.- Effects of Environmentally Acquired Heavy Metals and Nutrients on the Epigenome and Phenotype.- Fetal Imaging and Effects of Exposures on Growth and Function.- III.Developmental Risks of Exposures and Potential Translational Toxicology Therapeutics.- Ovarian Toxicity of Environmental Contaminants: 50 Shades of Grey.- The “Toxic” Effects of a Perinatal Obesogenic Environment: Maternal Obesity and Impacts on Future Generations.- The Role of Environmental Exposures in Preterm Birth.- The Impact of Environmental Stressors on DNA Methylation, Neurobehavioral Development and Chronic Physical Aggression: Prospects for Early Protective Interventions.- Coffee Health Effects from Early Fetal Development through Childhood and Adolescence.
Claude L. Hughes, M.D., Ph.D. is Executive Director in the Therapeutic Science & Strategy Unit within Quintiles Inc. He is board-certified in Obstetrics & Gynecology and Reproductive Endocrinology and Infertility. He is a Consulting Professor in the Department of Obstetrics & Gynecology, Duke University Medical Center and an Adjunct Professor in the Department of Mathematics, North Carolina State University and in the Department of Pathology/Comparative Medicine, Wake Forest University School of Medicine.

Since joining Quintiles in 2001, Dr. Hughes has served as a Medical Advisor on clinical trials or in due diligence assessment teams that evaluated pharmaceuticals, devices or tests for several medical indications. Therapeutic areas for clinical trials and/or product evaluation have included the following: 
1) Reproductive Medicine - female sex hormone therapy, male sex hormone therapy, contraception, infertility, in vitro fertilization-embryo transfer, polycystic ovary syndrome, SERMs, overactive bladder/urinary incontinence, endometriosis, preterm labor, ovarian cancer, cervical cancer, microbicides, dysmenorrhea, gynecologic infections, female and male sexual dysfunction, erectile dysfunction, BPH/LUTS, delayed puberty in boys, primary and secondary hypogonadism in boys.
2) General Endocrinology, Metabolism and Cardiovascular Diseases – osteoporosis prevention and treatment, diabetes mellitus, thyroid hormone replacement, growth hormone therapy in children, hypertension (including use of ambulatory blood pressure monitoring - ABPM) and chronic renal disease.
3) Other Medical Conditions – GERD, opioid-induced constipation, rheumatoid arthritis, sleep disorders, migraine headaches, neuropathic pain and psoriasis. 
4) Laboratory Testing Methods - genital cytologic screening and molecular biomarker screening.
5) Drug Delivery - new systems for tra

Defines a new field of therapeutic interventions that could protect, mitigate or reverse the adverse effects of earlier exposures

Explores the range of environmental exposures beyond exclusively that of environmental chemicals and highlights the categories of potential therapeutics

Future directions for research needs and opportunities